Skip to main content

Glenmark Pharma receives US FDA approval for voriconazole tablets

 

Clinical courses

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval from the United States Food & Drug Administration (FDA) for voriconazole tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).

Glenmark’s current portfolio consists of 102 products authorised for distribution in the US marketplace and 63 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>